Ireland,
June 2013
This report offers companies, investors, policymakers, and stakeholders crucial insight into Ireland; a nation that stands poised to cement its position as a premier pharmaceuticals power, not just within Europe, but globally. In addition to its blossoming R&D infrastructure, a large number of major healthcare, pharma, and medtech MNCs base manufacturing operations on the Emerald Isle due to its favorable taxation policies, incredible concentration of talent, membership of the EU single market, and easy access to a wide range of foreign markets. Despite its relatively small size, Ireland is the largest net exporter of pharmaceuticals in the EU and seventh largest globally, and could benefit significantly from the UK’s Brexit decision.
The report features in-depth exclusive interviews with leading figures from public institutions and private companies, comprehensive articles, and up-to-date facts and figures on Ireland’s healthcare and pharma sectors.
This report offers companies, investors, policymakers, and stakeholders crucial insight into Ireland; a nation that stands poised to cement its position as a premier pharmaceuticals power, not just within Europe, but globally. In addition to its blossoming R&D infrastructure, a large number of major healthcare, pharma, and medtech MNCs base manufacturing operations on the Emerald Isle due to its favorable taxation policies, incredible concentration of talent, membership of the EU single market, and easy access to a wide range of foreign markets. Despite its relatively small size, Ireland is the largest net exporter of pharmaceuticals in the EU and seventh largest globally, and could benefit significantly from the UK’s Brexit decision.
The report features in-depth exclusive interviews with leading figures from public institutions and private companies, comprehensive articles, and up-to-date facts and figures on Ireland’s healthcare and pharma sectors.
